Drugs used in incident systemic lupus erythematosus - results from the Finnish nationwide register 2000-2007

Lupus
P ElfvingO Kaipiainen-Seppänen

Abstract

The objectives of the study were to examine the initial, first-year anti-rheumatic outpatient therapy in patients with incident SLE, as well as the concomitant use of drugs for certain comorbidities, compared to the use in the general population. The Finnish nationwide register data on special reimbursements for medication costs was screened to identify the inception cohort of 566 adult SLE patients (87% females, mean age 46.5 ± 15.9 years) over the years 2000-2007. The patients were linked to the national Drug Purchase Register. Of those, 90% had purchased at least once some disease-modifying anti-rheumatic drugs (DMARDs) during the first year. Hydroxychloroquine was the most common (76%), followed by azathioprine (15%) and methotrexate (13%). With the exception of increase in mycophenolate mofetil, the proportions remained stable over the whole study period 2000-2007. Drugs for cardiovascular diseases, dyslipidemia, diabetes mellitus, hypothyroidism and obstructive pulmonary disease were more frequently purchased than in the sex- and age-adjusted population, with rate ratios ranging from 1.6 to 7.8. Over the years 2000-2007, almost all the patients with incident SLE in Finland started with a DMARD. Higher percentages of SLE p...Continue Reading

References

Oct 2, 1993·BMJ : British Medical Journal·P H BeardonT M MacDonald
Jan 10, 2002·Annals of the Rheumatic Diseases·D Pyne, D A Isenberg
May 2, 2007·Arthritis and Rheumatism·Emily C SomersAndrew J Hall
May 17, 2007·Annals of the Rheumatic Diseases·G BertsiasUNKNOWN Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics
Sep 1, 2007·Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases·María J MolinaLuis M Vilá
Jan 15, 2008·Autoimmunity Reviews·Andrea DoriaPiercalo Sarzi-Puttini
Dec 24, 2008·Annals of the Rheumatic Diseases·G Ruiz-IrastorzaM A Khamashta
Mar 21, 2009·Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases·Simone AppenzellerLilian T L Costallat
Apr 15, 2010·Arthritis Care & Research·Gabriela SchmajukEdward Yelin
Sep 4, 2010·Autoimmunity Reviews·Andrea DoriaLuca Iaccarino
Dec 24, 2010·Annals of the Rheumatic Diseases·M A PetriL S Magder
Jan 25, 2012·Rheumatology·Guillermo Ruiz-IrastorzaMunther Khamashta
Dec 25, 2012·Annals of the Rheumatic Diseases·Andrea DoriaIsabelle Boucot
Feb 21, 2013·Seminars in Arthritis and Rheumatism·Sara R SchoenfeldKaren H Costenbader
May 2, 2013·Maturitas·Preeta Kaur Chugh
Jun 25, 2013·Journal of Cardiovascular Pharmacology·George Stojan, Michelle Petri
Apr 18, 2014·Annals of the Rheumatic Diseases·Ronald F van VollenhovenMatthias Schneider

❮ Previous
Next ❯

Software Mentioned

RELESSER

Related Concepts

Related Feeds

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.